<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410811</url>
  </required_header>
  <id_info>
    <org_study_id>2012-4851</org_study_id>
    <nct_id>NCT02410811</nct_id>
  </id_info>
  <brief_title>Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease</brief_title>
  <official_title>Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use cardiac magnetic resonance imaging (CMR) and&#xD;
      echocardiographic tissue Doppler imaging to demonstrate a unique restrictive cardiomyopathy&#xD;
      of sickle cell disease. The investigators will characterize its frequency and how it might&#xD;
      change (e.g., presence/absence and severity) over a 2-year period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease (SCD) causes progressive cardiopulmonary morbidity, beginning in&#xD;
      childhood, which can ultimately be fatal. As a group, cardiopulmonary complications, such as&#xD;
      acute chest syndrome and sudden death, are now the most common causes of death in SCD,&#xD;
      especially in adolescents and adults.&#xD;
&#xD;
      Patients with SCD have features of both an anemia-related, high cardiac output state and a&#xD;
      restrictive cardiomyopathy (RCM). The investigators propose that this unique RCM is an&#xD;
      overlooked and understudied complication of SCD. RCM could explain the modest increases in&#xD;
      pulmonary artery pressure in patients with SCD, as measured by cardiac catheterization or&#xD;
      estimated by tricuspid regurgitant jet velocity (TRJV), which has often been attributed to a&#xD;
      primary pulmonary arterial hypertension (PAH). RCM could also be the cause of unexplained&#xD;
      sudden cardiac death in SCD, which is a feature of other forms of RCM.&#xD;
&#xD;
      The investigators overarching hypothesis is that increased reactive oxygen species&#xD;
      (ROS)-mediated angiotensin-1 receptor (AT1R)-TGFβ1 signaling is pro-fibrotic and, in&#xD;
      combination with vaso-occlusive ischemia-reperfusion injury, results in an age-dependent,&#xD;
      progressive RCM that can be detected by non-invasive cardiac imaging.&#xD;
&#xD;
      This pilot, longitudinal, observational study uses a novel, comprehensive, multimodal cardiac&#xD;
      imaging strategy, combining cutting-edge cardiac magnetic resonance imaging (CMR) and&#xD;
      echocardiographic tissue Doppler imaging (TDI), to demonstrate the unique RCM of SCD,&#xD;
      characterizing its frequency and the temporal evolution over a 2-year period. The&#xD;
      investigators will also correlate the RCM phenotype with biomarkers of ROS and renin&#xD;
      angiotensin system (RAS)-TGFβ1 signaling.&#xD;
&#xD;
      This research could change the investigators understanding of how SCD affects the heart and&#xD;
      lungs. The investigators propose studies that will change the current concept of primary&#xD;
      pulmonary vasculopathy to a cardiomyopathy-centered model with secondary pulmonary vascular&#xD;
      changes leading to sudden death. This translational pilot study will deliver a novel, clear,&#xD;
      quantifiable CMR phenotype with established diagnostic performance that will be used in phase&#xD;
      II/III clinical trials to test anti-fibrotic therapy to prevent or reverse SCD-related RCM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 31, 2014</start_date>
  <completion_date type="Actual">May 20, 2019</completion_date>
  <primary_completion_date type="Actual">January 29, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of the Diffuse Myocardial Fibrosis Phenotype</measure>
    <time_frame>Assessed annually over a 2-year period (3 assessments over 2 years)</time_frame>
    <description>The occurrence of an abnormally increased extracellular volume (ECV) measurement [i.e., the presence of the diffuse myocardial fibrosis phenotype] as assessed by cardiac magnetic resonance imaging (CMR) using T1 mapping before and after administration of gadolinium. Expressed as number of participants with the diffuse myocardial fibrosis phenotype in each stratum.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Stability of the Diffuse Myocardial Fibrosis Phenotype Over Time</measure>
    <time_frame>Assessed annually over a 2-year period (3 assessments over 2 years)</time_frame>
    <description>The occurrence of a change [from the baseline assessment] in the classification [presence or absence] of the diffuse myocardial fibrosis phenotype, which is defined as an abnormally increased extracellular volume (ECV) measurement as assessed by cardiac magnetic resonance imaging (CMR) using T1 mapping before and after administration of gadolinium. Expressed as number of participants who had a change in classification of the diffuse myocardial fibrosis phenotype [e.g., presence to absence, or absence to presence] during the 2-year study in each stratum.</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">33</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Age Stratum A</arm_group_label>
    <description>Age 6 to 13.99 years&#xD;
Cardiac magnetic resonance imaging (CMR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Stratum B</arm_group_label>
    <description>Age 14 to 20.99 years&#xD;
Detectible and quantifiable TRJV with reported value&#xD;
Cardiac magnetic resonance imaging (CMR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Stratum C</arm_group_label>
    <description>Age ≥21 years&#xD;
Detectible and quantifiable TRJV with reported value&#xD;
Cardiac magnetic resonance imaging (CMR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Stratum D</arm_group_label>
    <description>Age ≥6 years.&#xD;
Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at &lt;3 years of age, and for which there has been no interruption of therapy for &gt;6 consecutive months since the initiation of disease-modifying therapy.&#xD;
Cardiac magnetic resonance imaging (CMR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging (CMR)</intervention_name>
    <description>CMR is obtained on all participants in all arms/groups</description>
    <arm_group_label>Age Stratum A</arm_group_label>
    <arm_group_label>Age Stratum B</arm_group_label>
    <arm_group_label>Age Stratum C</arm_group_label>
    <arm_group_label>Age Stratum D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, DNA, and urine specimens.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Enrolling a maximum of 40 participants in the entire study across four age strata: A, 6 -&#xD;
        13.9 years; B, 14 - 20.9 years; C, 21 years and older; and D, 6 years and older.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sickle cell anemia (HbSS) or sickle-β°-thalassemia (HbSβ°) confirmed by hemoglobin&#xD;
             separation and identification techniques&#xD;
&#xD;
          -  Ability to cooperate with and undergo CMR without sedation or anesthesia.&#xD;
&#xD;
          -  Ability to cooperate with and undergo echocardiogram&#xD;
&#xD;
          -  Written informed consent in accordance with the institutional policies and federal&#xD;
             guidelines must be provided by the participant (if ≥18 years of age) or parent or&#xD;
             legally authorized guardian (if the participant is &lt;18 years of age) Minor&#xD;
             participants ≥11 years of age will be requested to provide assent&#xD;
&#xD;
        The following additional inclusion criterion applies to Age Stratum A:&#xD;
&#xD;
        Age 6 to 13.99 years&#xD;
&#xD;
        The following additional inclusion criteria apply to Age Stratum B:&#xD;
&#xD;
          -  Age 14 to 20.99 years&#xD;
&#xD;
          -  Detectible and quantifiable TRJV with reported value&#xD;
&#xD;
        The following additional inclusion criteria apply to Age Stratum C:&#xD;
&#xD;
          -  Age ≥21 years&#xD;
&#xD;
          -  Detectible and quantifiable TRJV with reported value&#xD;
&#xD;
        The following additional inclusion criteria apply to Stratum D:&#xD;
&#xD;
          -  Age ≥6 years.&#xD;
&#xD;
          -  Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both&#xD;
             (given concurrently, sequentially, or both)] that was initiated at &lt;3 years of age,&#xD;
             and for which there has been no interruption of therapy for &gt;6 consecutive months&#xD;
             since the initiation of disease-modifying therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to MRI or physical or behavioral factor that could degrade the&#xD;
             quality of MRI data or interfere with a participant's tolerance of the MRI, such as&#xD;
             permanent or semi-permanent metallic implants, including pacemakers and&#xD;
             defibrillators, or severe claustrophobia&#xD;
&#xD;
          -  Known ventricular septal defect (VSD) documented in medical record&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) &lt;60 mL/min/1.73 m2 (estimated by serum&#xD;
             creatinine or cystatin-C)&#xD;
&#xD;
          -  Pregnancy (documented by serum or urine pregnancy test)&#xD;
&#xD;
        The following additional inclusion criterion applies to strata A, B and C only:&#xD;
&#xD;
        - Current chronic transfusion therapy (defined as regular, approximately monthly,&#xD;
        transfusions of packed red blood cells given for at least 6 consecutive months for the&#xD;
        treatment of prevention of SCD-related complications with the plan to continue this therapy&#xD;
        at the time of potential enrollment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles T Quinn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael D Taylor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert J Fleck, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omar Y Niss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Powell AW, Alsaied T, Niss O, Fleck RJ, Malik P, Quinn CT, Mays WA, Taylor MD, Chin C. Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients. Pediatr Blood Cancer. 2019 Jun;66(6):e27703. doi: 10.1002/pbc.27703. Epub 2019 Mar 7.</citation>
    <PMID>30848046</PMID>
  </results_reference>
  <results_reference>
    <citation>Alsaied T, Niss O, Powell AW, Fleck RJ, Cnota JF, Chin C, Malik P, Quinn CT, Taylor MD. Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia. Pediatr Blood Cancer. 2018 Aug;65(8):e27113. doi: 10.1002/pbc.27113. Epub 2018 May 21.</citation>
    <PMID>29781568</PMID>
  </results_reference>
  <results_reference>
    <citation>Niss O, Fleck R, Makue F, Alsaied T, Desai P, Towbin JA, Malik P, Taylor MD, Quinn CT. Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia. Blood. 2017 Jul 13;130(2):205-213. doi: 10.1182/blood-2017-02-767624. Epub 2017 May 15.</citation>
    <PMID>28507082</PMID>
  </results_reference>
  <results_reference>
    <citation>Niss O, Quinn CT, Lane A, Daily J, Khoury PR, Bakeer N, Kimball TR, Towbin JA, Malik P, Taylor MD. Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. JACC Cardiovasc Imaging. 2016 Mar;9(3):243-52. doi: 10.1016/j.jcmg.2015.05.013. Epub 2016 Feb 17. Review.</citation>
    <PMID>26897687</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <results_first_submitted>October 7, 2020</results_first_submitted>
  <results_first_submitted_qc>October 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease (SCD)</keyword>
  <keyword>Cardiac Magnetic Resonance Imaging (CMR)</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Restrictive</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02410811/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stratum A (6-13.99 Years)</title>
          <description>Age 6 to 13.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.</description>
        </group>
        <group group_id="P2">
          <title>Stratum B (14-20.99 Years)</title>
          <description>Age 14 to 20.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
        </group>
        <group group_id="P3">
          <title>Stratum C (≥21 Years)</title>
          <description>Age ≥21 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
        </group>
        <group group_id="P4">
          <title>Stratum D (Early Treatment)</title>
          <description>Age ≥6 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at &lt;3 years of age, and for which there has been no interruption of therapy for &gt;6 consecutive months since the initiation of disease-modifying therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stratum A (6-13.99 Years)</title>
          <description>Age 6 to 13.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.</description>
        </group>
        <group group_id="B2">
          <title>Stratum B (14-20.99 Years)</title>
          <description>Age 14 to 20.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
        </group>
        <group group_id="B3">
          <title>Stratum C (≥21 Years)</title>
          <description>Age ≥21 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
        </group>
        <group group_id="B4">
          <title>Stratum D (Early Treatment)</title>
          <description>Age ≥6 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at &lt;3 years of age, and for which there has been no interruption of therapy for &gt;6 consecutive months since the initiation of disease-modifying therapy.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.0" spread="9.2"/>
                    <measurement group_id="B2" value="18.0" spread="9.1"/>
                    <measurement group_id="B3" value="35.8" spread="13.1"/>
                    <measurement group_id="B4" value="13.4" spread="6.9"/>
                    <measurement group_id="B5" value="22.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sickle cell disease genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Homozygous sickle cell anemia (HbSS)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sickle-β0-thalassemia (HbSβ0)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of the Diffuse Myocardial Fibrosis Phenotype</title>
        <description>The occurrence of an abnormally increased extracellular volume (ECV) measurement [i.e., the presence of the diffuse myocardial fibrosis phenotype] as assessed by cardiac magnetic resonance imaging (CMR) using T1 mapping before and after administration of gadolinium. Expressed as number of participants with the diffuse myocardial fibrosis phenotype in each stratum.</description>
        <time_frame>Assessed annually over a 2-year period (3 assessments over 2 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stratum A (6-13.99 Years)</title>
            <description>Age 6 to 13.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B (14-20.99 Years)</title>
            <description>Age 14 to 20.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
          </group>
          <group group_id="O3">
            <title>Stratum C (≥21 Years)</title>
            <description>Age ≥21 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
          </group>
          <group group_id="O4">
            <title>Stratum D (Early Treatment)</title>
            <description>Age ≥6 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at &lt;3 years of age, and for which there has been no interruption of therapy for &gt;6 consecutive months since the initiation of disease-modifying therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of the Diffuse Myocardial Fibrosis Phenotype</title>
          <description>The occurrence of an abnormally increased extracellular volume (ECV) measurement [i.e., the presence of the diffuse myocardial fibrosis phenotype] as assessed by cardiac magnetic resonance imaging (CMR) using T1 mapping before and after administration of gadolinium. Expressed as number of participants with the diffuse myocardial fibrosis phenotype in each stratum.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stability of the Diffuse Myocardial Fibrosis Phenotype Over Time</title>
        <description>The occurrence of a change [from the baseline assessment] in the classification [presence or absence] of the diffuse myocardial fibrosis phenotype, which is defined as an abnormally increased extracellular volume (ECV) measurement as assessed by cardiac magnetic resonance imaging (CMR) using T1 mapping before and after administration of gadolinium. Expressed as number of participants who had a change in classification of the diffuse myocardial fibrosis phenotype [e.g., presence to absence, or absence to presence] during the 2-year study in each stratum.</description>
        <time_frame>Assessed annually over a 2-year period (3 assessments over 2 years)</time_frame>
        <population>Stratum D participants had a single CMR assessment only; no longitudinal data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A (6-13.99 Years)</title>
            <description>Age 6 to 13.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B (14-20.99 Years)</title>
            <description>Age 14 to 20.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
          </group>
          <group group_id="O3">
            <title>Stratum C (≥21 Years)</title>
            <description>Age ≥21 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
          </group>
          <group group_id="O4">
            <title>Stratum D (Early Treatment)</title>
            <description>Age ≥6 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at &lt;3 years of age, and for which there has been no interruption of therapy for &gt;6 consecutive months since the initiation of disease-modifying therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Stability of the Diffuse Myocardial Fibrosis Phenotype Over Time</title>
          <description>The occurrence of a change [from the baseline assessment] in the classification [presence or absence] of the diffuse myocardial fibrosis phenotype, which is defined as an abnormally increased extracellular volume (ECV) measurement as assessed by cardiac magnetic resonance imaging (CMR) using T1 mapping before and after administration of gadolinium. Expressed as number of participants who had a change in classification of the diffuse myocardial fibrosis phenotype [e.g., presence to absence, or absence to presence] during the 2-year study in each stratum.</description>
          <population>Stratum D participants had a single CMR assessment only; no longitudinal data were collected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected for three, separate 30-day intervals over the entire study period of 2 years. Each 30-day interval was defined as starting with the study visit during which annual study activities were performed (e.g., cardiac magnetic resonance imaging [CMR]) and ending 30 days after that study visit. AEs were assessed as they occurred during each study visit, and AEs that occurred in the 30 days after each study visit were collected by scripted phone call from the study team.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stratum A (6-13.99 Years)</title>
          <description>Age 6 to 13.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.</description>
        </group>
        <group group_id="E2">
          <title>Stratum B (14-20.99 Years)</title>
          <description>Age 14 to 20.99 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
        </group>
        <group group_id="E3">
          <title>Stratum C (≥21 Years)</title>
          <description>Age ≥21 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Detectible and quantifiable tricuspid regurgitant jet velocity (TRJV).</description>
        </group>
        <group group_id="E4">
          <title>Stratum D (Early Treatment)</title>
          <description>Age ≥6 years.&#xD;
Sickle cell anemia or sickle-β0-thalassemia.&#xD;
Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at &lt;3 years of age, and for which there has been no interruption of therapy for &gt;6 consecutive months since the initiation of disease-modifying therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-occlusive pain episode</sub_title>
                <description>Sickle cell pain crisis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All participants in strata A, B and C had severe diffuse myocardial fibrosis. That is, all participants had the phenotype for which we assessed, so correlative studies (e.g., affected vs. non-affected) could not be performed. Therefore, we amended the protocol and opened an additional, fourth stratum (D) to study individuals who were previously not eligible for inclusion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Charles T. Quinn</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>5138033086</phone>
      <email>charles.quinn@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

